FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| AB-101 | Relapsed or Refractory Hodgkin Lymphoma | PHASE2 | TERMINATED |
| AFM13 | Relapsed or Refractory Hodgkin Lymphoma | PHASE2 | TERMINATED |
| Allogeneic NK Cells | Refractory Rheumatoid Arthritis (RA) | PHASE2 | RECRUITING |
| Cyclophosphamide | Relapsed or Refractory Hodgkin Lymphoma | PHASE2 | TERMINATED |
| Fludarabine | Relapsed or Refractory Hodgkin Lymphoma | PHASE2 | TERMINATED |
| Interleukin-2 | Relapsed or Refractory Hodgkin Lymphoma | PHASE2 | TERMINATED |
| AB-201 | Breast Cancer | PHASE1 | WITHDRAWN |
| Bendamustine | Non Hodgkin Lymphoma | PHASE1 | COMPLETED |
| GCC2005 | Lymphoma, T-Cell | PHASE1 | RECRUITING |
| Obinutuzumab | Lupus Nephritis - WHO Class III | PHASE1 | ACTIVE_NOT_RECRUITING |
ARTV holds $21M in cash and burns about $17.8M/quarter from operations, giving an estimated runway of 3.5 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ARTV free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-06-16 | RA Capital Healthcare Fund L |
Purchase | $142.5M |
| 2026-06-16 | RA Capital Healthcare Fund L |
Purchase | $149.6M |
| 2026-06-16 | RA Capital Healthcare Fund L |
Purchase | $149M |
| 2026-06-11 | RA Capital Healthcare Fund L |
Purchase | $108.4M |
| 2026-06-11 | RA Capital Healthcare Fund L |
Purchase | $109.8M |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ARTV and 2 more tickers of your choice.
Create Free Account →